1. |
濮天, 方强, 陈子祥, 等. 肝内胆管癌发病机制及治疗相关进展. 中华消化外科杂志, 2020, 19(6): 697-702.
|
2. |
高博, 赵海鹰. 肝内胆管癌的流行病学特征及危险因素研究进展. 现代肿瘤医学, 2020, 28(7): 1214-1217.
|
3. |
毕超, 王黎明, 安松林, 等. 123例肝内胆管癌患者手术切除后的生存分析. 中华肿瘤杂志, 2016, 38(6): 466-471.
|
4. |
敖建阳, 程庆保, 刘辰, 等. 肝内胆管癌的治疗难点及应对策略. 肝胆胰外科杂志, 2020, 32(6): 321-325.
|
5. |
Reich M, Deutschmann K, Sommerfeld A, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut, 2016, 65(3): 487-501.
|
6. |
Li ZY, Zhou JJ, Luo CL, et al. Activation of TGR5 alleviates inflammation in rheumatoid arthritis peripheral blood mononuclear cells and in mice with collagen Ⅱ-induced arthritis. Mol Med Rep, 2019, 20(5): 4540-4550.
|
7. |
巢佳灯, 秦锡虎. 胆汁酸G蛋白偶联受体5在消化道疾病中的研究进展. 医学综述, 2019, 25(6): 1128-1132.
|
8. |
王馨悦, 李楠, 董兵, 等. mortalin蛋白在宫颈鳞癌中的表达及其对肿瘤转移能力的影响. 中国病理生理杂志, 2020, 36(1): 146-151.
|
9. |
Jin H, Ji M, Chen L, et al. The clinicopathological significance of mortalin overexpression in invasive ductal carcinoma of breast. J Exp Clin Cancer Res, 2016, 35(1): 42-51.
|
10. |
Li AD, Xie XL, Qi W, et al. TGR5 promotes cholangiocarcinoma by interacting with mortalin. Exp Cell Res, 2020, 389(2): 111855-111860.
|
11. |
李增山, 李青. 2010年版消化系统肿瘤WHO分类解读. 中华病理学杂志, 2011, 40(5): 351-354.
|
12. |
许良中, 杨文涛. 免疫组织化学反应结果的判断标准. 中国癌症杂志, 1996, 6(4): 229-231.
|
13. |
Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol, 2020, 72(1): 95-103.
|
14. |
傅俊, 李俊, 项红军, 等. 肝切除切缘的距离对肝内胆管癌伴乙型肝炎肝硬化预后的影响. 肝胆外科杂志, 2017, 25(2): 89-94.
|
15. |
李永胜, 孙保君. 肝内胆管癌手术治疗的预后影响因素分析. 实用癌症杂志, 2016, 31(4): 610-612.
|
16. |
van Nierop FS, Scheltema MJ, Eggink HM, et al. Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol, 2017, 5(3): 224-233.
|
17. |
Keitel V, Stindt J, Häussinger D. Bile acid-activated receptors: GPBAR1 (TGR5) and other G protein-coupled receptors. Handb Exp Pharmacol, 2019, 256(1): 19-49.
|
18. |
Ma K, Tang D, Yu C, et al. Progress in research on the roles of TGR5 receptor in liver diseases. Scand J Gastroenterol, 2021, 56(6): 717-726.
|
19. |
Carino A, Graziosi L, D'Amore C, et al. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. Oncotarget, 2016, 7(38): 61021-61035.
|
20. |
金海丹, 周宪春, 张松男, 等. Mortalin促进人乳腺癌细胞MDA-MB231的恶性进展. 基础医学与临床, 2015, 35(6): 833-835.
|
21. |
Wu PK, Hong SK, Starenki D, et al. Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. Oncogene, 2020, 39(21): 4257-4270.
|
22. |
Kiraly VTR, Dores-Silva PR, Serrão VHB, et al. Thermal aggregates of human mortalin and Hsp70-1A behave as supramolecular assemblies. Int J Biol Macromol, 2020, 146(1): 320-331.
|
23. |
Wadhwa R, Ryu J, Ahn HM, et al. Functional significance of point mutations in stress chaperone mortalin and their relevance to Parkinson disease. J Biol Chem, 2015, 290(13): 8447-8456.
|
24. |
Yun CO, Bhargava P, Na Y, et al. Relevance of mortalin to cancer cell stemness and cancer therapy. Sci Rep, 2017, 7(1): 42016-42019.
|
25. |
Xu M, Zhang Y, Cui M, et al. Mortalin contributes to colorectal cancer by promoting proliferation and epithelial–mesenchymal transition. IUBMB Life, 2020, 72(4): 771-781.
|
26. |
陈静, 李建生, 刘文斌, 等. Mortalin在肝癌中的表达及其与血管生成和上皮间质转化的关系. 安徽医科大学学报, 2014, 49(6): 795-799.
|